Online inquiry

IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1689MR)

This product GTTS-WQ1689MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Atherosclerosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1689MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5776MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ1791MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ8647MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ13922MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ4232MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ2846MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ12368MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ6717MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS 1024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW